We are live on
!
Find out more
TCM
TCG Crossover Management Portfolio holdings
AUM
$3.5B
1-Year Est. Return
1,165.83%
This Fund
S&P 500
This Quarter
Est. Return
-10.91%
1 Year Est. Return
+1,165.83%
3 Year Est. Return
+3,168.76%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.02B
AUM Growth
-$157M
(-13%)
Cap. Flow
+$131M
Cap. Flow
% of AUM
12.82%
Top 10 Holdings %
Top 10 Hldgs %
52.04%
Holding
41
New
5
Increased
4
Reduced
2
Closed
3
Top Buys
| 1 |
UPB
Upstream Bio Inc
UPB
|
+$62.6M |
| 2 |
Tango Therapeutics
TNGX
|
+$49.8M |
| 3 |
Dianthus Therapeutics
DNTH
|
+$38.6M |
| 4 |
EyePoint Inc
EYPT
|
+$24.7M |
| 5 |
RAPT
RAPT Therapeutics
RAPT
|
+$20.9M |
Top Sells
| 1 |
Edgewise Therapeutics
EWTX
|
+$56.4M |
| 2 |
Keros Therapeutics
KROS
|
+$17.1M |
| 3 |
Tarsus Pharmaceuticals
TARS
|
+$7.62M |
| 4 |
AN2 Therapeutics
ANTX
|
+$1.66M |
| 5 |
ADVM
Adverum Biotechnologies
ADVM
|
+$1.43M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
CG Oncology
CGON
$6.13B
| $105M | 10.29% |
3,670,206
| – | – |
|
2
Dyne Therapeutics
DYN
$3.76B
| $62.4M | 6.1% |
2,650,150
| – | – |
|
3
Xencor
XNCR
$1.11B
| $56.4M | 5.51% |
2,452,138
+25,000
| +1% | +$574K |
|
4
Cogent Biosciences
COGT
$6.48B
| $54.3M | 5.31% |
6,964,375
| – | – |
|
|
CNTA
5
DELISTED
Centessa Pharmaceuticals
CNTA
| $48.4M | 4.73% |
2,890,816
| – | – |
|
6
Ocular Therapeutix
OCUL
$2.01B
| $45.4M | 4.44% |
5,319,148
| – | – |
|
|
UPB
7
Upstream Bio Inc
UPB
$393M
| $44.9M | 4.38% |
+2,801,763
| New | +$62.6M |
|
|
ABVX
8
Abivax
ABVX
$12B
| $44.3M | 4.33% |
6,056,596
| – | – |
|
9
Savara
SVRA
$1.13B
| $38M | 3.71% |
12,362,205
| – | – |
|
|
10
Tango Therapeutics
TNGX
$4.5B
| $33.2M | 3.24% |
+10,736,000
| New | +$49.8M |
|
|
11
Dianthus Therapeutics
DNTH
$5.21B
| $32.7M | 3.2% |
+1,501,624
| New | +$38.6M |
|
12
Disc Medicine
IRON
$2.81B
| $30.9M | 3.02% |
486,957
| – | – |
|
13
Mineralys Therapeutics
MLYS
$2.39B
| $30.4M | 2.97% |
2,470,265
| – | – |
|
|
TRML
14
DELISTED
Tourmaline Bio
TRML
| $30M | 2.93% |
1,477,593
| – | – |
|
15
Structure Therapeutics
GPCR
$3.27B
| $28.8M | 2.82% |
1,063,000
| – | – |
|
16
Tyra Biosciences
TYRA
$1.88B
| $27.6M | 2.7% |
1,989,103
| – | – |
|
|
17
EyePoint Inc
EYPT
$1.09B
| $26.6M | 2.6% |
3,572,335
+2,650,000
| +287% | +$24.7M |
|
|
CDTX
18
DELISTED
Cidara Therapeutics
CDTX
| $26.1M | 2.55% |
+1,005,901
| New | +$16.3M |
|
|
THRD
19
DELISTED
Third Harmonic Bio
THRD
| $25.8M | 2.52% |
2,505,424
+90,424
| +4% | +$1.13M |
|
|
SLNO
20
DELISTED
Soleno Therapeutics
SLNO
| $24.7M | 2.42% |
550,000
| – | – |
|
|
ATXS
21
DELISTED
Astria Therapeutics
ATXS
| $24.7M | 2.41% |
2,761,861
| – | – |
|
22
Fulcrum Therapeutics
FULC
$233M
| $24.7M | 2.41% |
5,250,000
| – | – |
|
|
SLN
23
Silence Therapeutics
SLN
$516M
| $20.9M | 2.04% |
3,033,560
| – | – |
|
|
RAPT
24
DELISTED
RAPT Therapeutics
RAPT
| $19.8M | 1.93% |
+1,641,908
| New | +$20.9M |
|
25
Amylyx Pharmaceuticals
AMLX
$1.89B
| $17.6M | 1.72% |
4,643,812
| – | – |
|
Similar funds
DILIC
IIM
KCM
ACM
BCP
AL
ACA
MSC